Sarcoma-bearing mice were randomized into four treatment groups when tumors reached 75–125 mm3: isotype control antibody (ISO), anti-PD-1 antibody, ISO + 20 Gy (ISO + RT), and anti-PD-1 + 20 Gy (anti-PD-1 + RT). This evidence concerns the gene PDCD1 and sarcoma.